Compositions and methods for treating inflammatory disorders

• US 9,623,000 B2
• Filed: 07/29/2009
• Issued: 04/18/2017
• Est. Priority Date: 07/31/2008
• Status: Active Grant

• Current Assignee: Dekel Pharmaceuticals, Ltd. (SciSparc Ltd.)
• Original Assignee: Dekel Pharmaceuticals, Ltd. (SciSparc Ltd.)
• Inventors: Kindler, Seth, Shmulewitz, Ascher
• Primary Examiner(s): Kwon, Brian-Yong
• Assistant Examiner(s): Chang, Kyung Sook
• Application Number:
  US13/056,872
• Publication Number:
  US 20110195096A1
• Time in Patent Office: 2,820 Days
• Field of Search: None
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/20 having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61L 2300/222 Steroids, e.g. corticosteroids
• CPC Class Codes: A61L 2300/41 Anti-inflammatory agents, e.g. NSAIDs
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Compositions which include a corticosteroid in combination with an additional compound active in treatment of an inflammatory disorder are provided.

Claims

1. A non-aqueous pharmaceutical composition comprising 0.5% N-palmitoylethanolamine by weight and 600 nmole hydrocortisone and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1, wherein said pharmaceutically acceptable carrier is suitable for topical administration.

3. The pharmaceutical composition of claim 1, wherein said pharmaceutically acceptable carrier is suitable for mucosal administration.

4. The pharmaceutical composition of claim 1, wherein said pharmaceutically acceptable carrier is suitable for oral administration.

5. A medical device comprising the pharmaceutical composition of claim 1.

6. The medical device of claim 5, wherein said pharmaceutical composition forms a coating of the medical device.

7. The pharmaceutical composition of claim 1, formulated as a crè

me, an ointment, a solution, a patch, a spray, a lotion, a liniment, a varnish, or a solid preparation.